INVO Fertility, Inc. (NAYA) Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on April 18, 2025, covering events occurring on April 14 and April 16, 2025. The registrant, formerly known as NAYA Biosciences, Inc., is a Nevada corporation with principal executive offices in Sarasota, FL. The company's common stock trades on The Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and listing status rather than financial performance.
Material Changes
- Corporate Name Change: On April 14, 2025, the company officially changed its name from NAYA Biosciences, Inc. to INVO Fertility, Inc. via an Amendment to Articles of Incorporation filed with the Nevada Secretary of State.
- Ticker Symbol Change: The company intends to cease trading under the symbol "NAYA" and begin trading under the new symbol "IVF" on the Nasdaq Capital Market as promptly as possible.
- Nasdaq Delisting Notice: On April 16, 2025, the company received a letter from Nasdaq indicating a failure to satisfy Listing Rule 5250(c)(1) due to the untimely filing of its Annual Report on Form 10-K for the year ended December 31, 2024.
Outlook, Risks, and Management Commentary
Compliance Timeline: The Nasdaq notice has no immediate effect on the listing, and the stock continues to trade. The company has 60 calendar days from the date of the letter to submit a plan to regain compliance. If accepted, Nasdaq may grant an exception of up to 180 calendar days from the original due date, extending the deadline to October 13, 2025.
Management Expectation: Management expects to be in a position to submit the overdue Form 10-K as soon as practicable.
Investor Verification Checklist
- Verify the exact date the new ticker symbol "IVF" becomes active on Nasdaq.
- Monitor the submission of the delinquency plan to Nasdaq within the 60-day window.
- Confirm the filing date of the overdue Form 10-K for the fiscal year ended December 31, 2024.
- Review the Amendment to Articles of Incorporation (Exhibit 3.1) for any additional corporate changes.